Effect of MRI-based semiautomatic size-assessment in cerebral metastases on the RANO-BM classification
- 9 Downloads
Evaluation of a semiautomatic software algorithm for magnetic resonance imaging (MRI)-based assessment of cerebral metastases in cancer patients.
Material and Methods
Brain metastases (n = 131) in 38 patients, assessed by contrast-enhanced MRI, were retrospectively evaluated at two timepoints (baseline, follow-up) by two experienced neuroradiologists in a blinded manner. The response assessment in neuro-oncology (RANO) criteria for brain metastases (RANO-BM) were applied by means of a software (autoRANO-BM) as well as manually (manRANO-BM) at an interval of 3 weeks.
The average diameter of metastases was 12.03 mm (SD ± 6.66 mm) for manRANO-BM and 13.97 mm (SD ± 7.76 mm) for autoRANO-BM. Diameter figures were higher when using semiautomatic measurements (median = 11.8 mm) as compared to the manual ones (median = 10.2 mm; p = 0.000). Correlation coefficients for intra-observer variability were 0.993 (autoRANO-BM) and 0.979 (manRANO-BM). The interobserver variability (R1/R2) was 0.936/0.965 for manRANO-BM and 0.989/0.998 for autoRANO-BM. A total of 19 lesions (15%) were classified differently when using semiautomatic measurements. In 14 cases with suspected disease progression by manRANO-BM a stable course was found according to autoRANO-BM.
Computerized measuring techniques can aid in the assessment of cerebral metastases by reducing examiner-dependent effects and may consequently result in a different classification according to RANO-BM criteria.
KeywordsCerebral metastases Semiautomatic measurement RECIST Response group Radiooncological imaging
Compliance with ethical guidelines
Conflict of interest
H.-C. Bauknecht, R. Klingebiel, P. Hein, C. Wolf, L. Bornemann, E. Siebert and G. Bohner declare that they have no competing interests.
This study has been approved by the ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
- 1.Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY; Response Assessment in Neuro-Oncology (RANO) group. Response assessment criteria for brain metastases: Proposal from the RANO Group. Lancet Oncol. 2015;16:e270–8.CrossRefGoogle Scholar
- 3.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefGoogle Scholar
- 7.Bornemann L, Kuhnigk JM, Dicken V, Zidowitz S, Kuemmerlen B, Krass S, Peitgen HO, Wein BB, Schubert H, Shin HO, Wormanns D. Informatics in radiology (infoRAD): new tools for computer assistance in thoracic CT part 2. Therapy monitoring of pulmonary metastases. Radiographics. 2005;25:841–8.CrossRefGoogle Scholar
- 17.Vogel MN, Vonthein R, Schmücker S, Maksimovich O, Bethge W, Dicken V, Claussen CD, Horger M. Automated pulmonary nodule volumetry with an optimized algorithm. Accuracy at different slice thicknesses compared to unidimensional and bidimensional measurements. Rofo. 2008;180:791–7.CrossRefGoogle Scholar
- 18.Gahrmann R, van den Bent M, van der Holt B, Vernhout RM, Taal W, Vos M, de Groot JC, Beerepoot LV, Buter J, Flach ZH, Hanse M, Jasperse B, Smits M. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—A report from the BELOB trial. Neuro Oncol. 2017;19:853-61.CrossRefGoogle Scholar